



## Air pollution and poverty: a deadly combination in idiopathic pulmonary fibrosis?

Copyright ©The authors 2021. For reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 17 June 2021  
Accepted: 04 Aug 2021

To the Editor:

Disparities in respiratory health can be partly explained by environmental exposure (in particular to air pollution) and socioeconomic inequalities [1]. Although idiopathic pulmonary fibrosis (IPF) is a rare disease, there has been growing interest over the last years in the role of air pollution in its incidence and natural history.

In a recent issue of the *European Respiratory Journal*, YOON *et al.* [2] provide new evidence on the impact of air pollution on IPF mortality in a large retrospective monocentric cohort of Korean patients, using a validated pollution dispersion model to estimate individual residential-level air pollution exposure. After adjustment for individual and area-level potential confounders, they found an adverse effect of long-term exposure to NO<sub>2</sub> but not to PM<sub>10</sub> (particles with a 50% cut-off aerodynamic diameter of 10 µm) on survival. Conversely, in a French prospective multicentric cohort, our team found an association between IPF mortality and long-term exposure to PM<sub>10</sub> and PM<sub>2.5</sub>, but not to NO<sub>2</sub> [3]. While discussing carefully this discrepancy in results and raising in particular the methodological differences regarding the exposure assessment, both in terms of measurement (dispersion model *versus* air quality stations) and exposure-period (1 year *versus* cumulative exposure during follow-up), the authors did not consider the difference in pollutant levels between the two countries. Due to differences in observed air pollutant levels between Korea and France, there would be a gradient in the health effects due to air pollution exposure and thus a varied health impact.

Air quality assessment faces many difficulties in estimating exposure of patients suffering from respiratory diseases, and possibly even more in the case of IPF. Indeed, it is not uncommon for an IPF patient to have relocated at the time of IPF diagnosis, either to get closer to their healthcare referral centre or to move to another region for retirement as the disease affects older people. This may be problematic, because exposure in IPF patients should be studied over prolonged periods of time starting prior to the onset of disease, such as in asbestosis, in which remote past exposure to pro-fibrosing asbestos fibres is important to consider [4]. Furthermore, IPF is a rare disease and in order to enrol a significant number of patients, the inclusion period of studies needs to be quite long. Finally, the quality of air has improved on average over time in many countries, as the authors pointed out, which makes it difficult to evaluate the risk associated with exposure.

Interestingly, YOON *et al.* [2] observed the association between NO<sub>2</sub> and IPF mortality when area-level covariates (educational level and gross regional domestic product as a proxy for income) were considered in addition to individual-level covariates. Indeed, socioeconomic factors are important to take into account because they have a significant impact on health [2]. Income is a social indicator of life expectancy [5], and educational level captures childhood socioeconomic conditions and largely determines income [6]. It is well known that socioeconomic position is related to air pollution. Areas with low socioeconomic status communities suffer greater air pollution, and some ethnic groups are more likely to live closer to major sources of pollution [7]. In our French cohort we recently showed that IPF patients with lower area-level income were more likely to be of non-European origin, to have occupational exposure, and they tended to have a higher cumulative exposure to PM<sub>2.5</sub> compared to higher area-level income [8]. Yet, importantly, poorer IPF patients had a worse survival even after adjusting for geographical origin, and occupational exposure [8]. These observations suggest that income is a multifactorial social marker in which a variety of

Shareable abstract (@ERSpublications)

**Socioeconomic level influences co-exposure throughout life, and by the time IPF appears, social conditions and environmental exposures have already been at work for many years**

<https://bit.ly/3iAmS8R>

**Cite this article as:** Sesé L, Annesi-Maesano I, Cavalin C, *et al.* Air pollution and poverty: a deadly combination in idiopathic pulmonary fibrosis? *Eur Respir J* 2021; 58: 2101714 [DOI: 10.1183/13993003.01714-2021].



factors potentially important in IPF are embodied, including delayed access to medical care or inadequate education about preventive measures regarding health habits, comorbidities or IPF itself (e.g. vaccinations, smoking cessation, control of cardiovascular risk factors). For all those reasons, the respective impact of area-level education and income on IPF survival in the Korean cohort should be uncovered.

Air pollution and poverty constitute a deadly mix in IPF. Precarity can potentiate the deleterious effect of environmental exposures as well as certain genetic predispositions such as telomere length [9]. Moreover, socioeconomic status may influence co-exposures in pre-natal period and throughout life, and influence primary, secondary and tertiary disease prevention [1]. And by the time IPF appears, social conditions and environmental exposures have already been at work for many years. Thus, as suggested by some authors, an exposome approach, involving research in life and social sciences, would provide a better understanding of the influence of the environment on the genesis and severity of IPF [10].

**Lucile Sesé<sup>1,2,3</sup>, Isabella Annesi-Maesano<sup>4</sup>, Catherine Cavalin<sup>5,6,7</sup> and Hilario Nunes<sup>2</sup>**

<sup>1</sup>AP-HP, Service de Physiologie, Hôpital Avicenne - Université Sorbonne Paris Nord, INSERM 1272, «Hypoxie et Poumon: pneumopathies fibrosantes, modulations ventilatoires et circulatoires», Bobigny, France. <sup>2</sup>Centre de référence des maladies pulmonaires rares (site constitutif), AP-HP, Service de Pneumologie, Hôpital Avicenne - Université Sorbonne Paris Nord, INSERM 1272, «Hypoxie et Poumon: pneumopathies fibrosantes, modulations ventilatoires et circulatoires», Bobigny, France. <sup>3</sup>EPAR, IPLESP UMR-S 1136, INSERM et Sorbonne Université, Paris, France. <sup>4</sup>INSERM and Montpellier University, Institute Desbrest of Epidemiology and Public Health, IDESP, Montpellier, France. <sup>5</sup>Institut de recherche interdisciplinaire en sciences sociales (IRISSO, UMR CNRS-INRA 7170-1427), Paris-Dauphine Université, PSL - Paris, Paris, France. <sup>6</sup>Laboratoire interdisciplinaire d'évaluation des politiques publiques de Sciences Po (LIEPP), Sciences Po, Paris, France. <sup>7</sup>Centre d'études de l'emploi et du travail (CEET, CNAM), Noisy-le-Grand, France.

Corresponding author: Lucile Sesé ([lucile.sese@aphp.fr](mailto:lucile.sese@aphp.fr))

Conflict of interest: L. Sesé reports personal fees for consultancy and non-financial support for meeting attendance from Roche/Genentech, non-financial support for meeting attendance from Boehringer Ingelheim, personal fees for consultancy from Chiesi, AstraZeneca and Novartis, outside the submitted work. I. Annesi-Maesano has nothing to disclose. C. Cavalin has nothing to disclose. H. Nunes reports grants and personal fees for consultancy from Roche/Genentech and Boehringer Ingelheim, personal fees for advisory board work from Galapagos, other (clinical trial investigator) from Sanofi, Gilead, Novartis and Galecto Biotech AB, during the conduct of the study; personal fees for advisory board work from Actelion Pharmaceuticals, outside the submitted work.

## References

- Schraufnagel DE, Blasi F, Kraft M, *et al.* An official American Thoracic Society/European Respiratory Society policy statement: disparities in respiratory health. *Am J Respir Crit Care Med* 2013; 188: 865–871.
- Yoon H-Y, Kim S-Y, Kim O-J, *et al.* Nitrogen dioxide increases the risk of mortality in idiopathic pulmonary fibrosis. *Eur Respir J* 2021; 57: 2001877.
- Sesé L, Nunes H, Cottin V, *et al.* Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis. *Thorax* 2018; 73: 145–150.
- Roggli VL, Gibbs AR, Attanoos R, *et al.* Pathology of asbestosis—An update of the diagnostic criteria: report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. *Arch Pathol Lab Med* 2010; 134: 19–22.
- Chetty R, Stepner M, Abraham S, *et al.* The association between income and life expectancy in the United States, 2001–2014. *JAMA* 2016; 315: 1750–1766.
- Galobardes B. Indicators of socioeconomic position (part 1). *J Epidemiol Community Health* 2006; 60: 7–12.
- Hajat A, Hsia C, O'Neill MS. Socioeconomic disparities and air pollution exposure: a global review. *Curr Environ Health Rep* 2015; 2: 440–450.
- Sesé L, Caliez J, Annesi-Maesano I, *et al.* Low income and outcome in idiopathic pulmonary fibrosis: an association to uncover. *Respir Med* 2021; 183: 106415.
- Miri M, Nazarzadeh M, Alahabadi A, *et al.* Air pollution and telomere length in adults: a systematic review and meta-analysis of observational studies. *Environ Pollut* 2019; 244: 636–647.
- Johannson KA, Balmes JR, Collard HR. Air pollution exposure: a novel environmental risk factor for interstitial lung disease? *Chest* 2015; 147: 1161–1167.